{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-23-039661","form_type":"8-K","ticker":"PDSB","cik":"0001472091","company_name":"PDS Biotechnology Corp","filed_at":"2023-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.021503+00:00","generated_at":"2026-06-11T10:45:33.977714+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"PDS Biotech Q2 net loss $11.5M ($0.37/sh); cash $60.6M; Phase 3 protocol submitted to FDA","bullets":["Net loss of $11.5M ($0.37 per share) vs. $5.8M ($0.20 per share) in Q2 2022.","R&D expenses rose to $8.0M from $3.8M; G&A rose to $4.7M from $3.3M.","Cash and equivalents $60.6M; management says sufficient for 12 months.","Submitted final Phase 3 VERSATILE-003 protocol to FDA to start Q4 2023.","VERSATILE-002 interim data showed 12-month OS rate of 87% with favorable safety."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-23-039661","json":"https://secwatch.observer/filing/0001140361-23-039661.json","markdown":"https://secwatch.observer/filing/0001140361-23-039661.md","text":"https://secwatch.observer/filing/0001140361-23-039661.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1472091/000114036123039661/0001140361-23-039661-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1472091/000114036123039661/brhc20057492_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T10:45:33.977714+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3f46dc8987ae7079f423b6a810a85e6a0a8f813a","claim":"PDS Biotechnology Corp reported for the three and six months ended June 30, 2023 results: net income Net loss for the three months ended June 30, 2023 was approximately $11.5 million, or ($0.37) per basic share and dilute, EPS ($0.37) per basic share and diluted share.","evidence_excerpt":"Net loss for the three months ended June 30, 2023 was approximately $11.5 million, or ($0.37) per basic share and diluted share","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1472091/000114036123039661/0001140361-23-039661-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"for the three and six months ended June 30, 2023"},{"label":"Net income","value":"Net loss for the three months ended June 30, 2023 was approximately $11.5 million, or ($0.37) per basic share and dilute"},{"label":"EPS","value":"($0.37) per basic share and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}